<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692429</url>
  </required_header>
  <id_info>
    <org_study_id>CYAD-N2L-101</org_study_id>
    <nct_id>NCT03692429</nct_id>
  </id_info>
  <brief_title>alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells</brief_title>
  <acronym>alloSHRINK</acronym>
  <official_title>An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celyad Oncology SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celyad Oncology SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical&#xD;
      activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered&#xD;
      after standard chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study aims to determine and confirm the recommended dose of the allogeneic CYAD-101&#xD;
      cells after standard FOLFOX or FOLFIRI chemotherapy in patients with unresectable metastatic&#xD;
      colorectal cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">February 17, 2036</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of Dose Limiting Toxicities</measure>
    <time_frame>Up to 82 days post first CYAD-101 Infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Unresectable Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CYAD-101 with FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion after standard FOLFOX chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYAD-101 with FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion after standard FOLFIRI chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYAD-101</intervention_name>
    <description>Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells</description>
    <arm_group_label>CYAD-101 with FOLFIRI</arm_group_label>
    <arm_group_label>CYAD-101 with FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>5-FU, leucovorin and oxaliplatin</description>
    <arm_group_label>CYAD-101 with FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>5-FU, leucovorin and irinotecan</description>
    <arm_group_label>CYAD-101 with FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven metastatic adenocarcinoma of the colon or rectum.&#xD;
&#xD;
               1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.&#xD;
&#xD;
               2. Recurrent/progressing disease after at least one line of systemic therapy for&#xD;
                  metastatic disease.&#xD;
&#xD;
               3. Unequivocal and measurable disease by Response Evaluation Criteria in Solid&#xD;
                  Tumors (RECIST version 1.1).&#xD;
&#xD;
               4. FOLFOX segment: Neurotoxicity less than or equal to Common Terminology Criteria&#xD;
                  for Adverse Events (CTCAE) Grade 1 from previous chemotherapy.&#xD;
&#xD;
               5. FOLFIRI segment: Documented progressive disease (PD) under FOLFIRI treatment,&#xD;
                  with or without targeted therapy, given within 3 months prior to study&#xD;
                  registration. Anti-cancer therapy post FOLFIRI-documented PD prior to study&#xD;
                  registration is authorized if discontinued at least 7 days before the planned&#xD;
                  study registration. Radiotherapy is not authorized.&#xD;
&#xD;
          2. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             0 or 1.&#xD;
&#xD;
          3. The patient must have adequate bone marrow reserve, hepatic, renal, pulmonary and&#xD;
             cardiac functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a confirmed or history of tumor involvement in the central nervous&#xD;
             system (CNS).&#xD;
&#xD;
          2. Any non-cancer-directed investigational agent within 3 weeks before the planned day&#xD;
             for the first CYAD-101 administration.&#xD;
&#xD;
          3. Filgrastim (Granulocyte-Colony-Stimulating Factor [G-CSF]) or similar growth factors&#xD;
             within 7 days before the planned day for the first CYAD-101 administration.&#xD;
&#xD;
          4. Prior allogeneic stem cell transplantation, chimeric antigen receptor therapy or other&#xD;
             genetically modified T-cell therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celyad Oncology Medical Monitor, MD, PhD</last_name>
    <phone>+3210394100</phone>
    <email>clinicaltrials@celyad.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Dae Won, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kim Dae Won</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Dubuisson</last_name>
    </contact>
    <investigator>
      <last_name>Alain Hendlisz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Prenen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hans Prenen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Mars√©</last_name>
    </contact>
    <investigator>
      <last_name>Eric Van Cutsem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

